In November 2024, Huayi Pharmaceuticals (Anhui) Co., Ltd. reached a significant milestone as its Shanghai Road site and Shenyang Road site successfully pass EU official on-site inspection. This is also the fifth time that our company has successfully passed EU official inspection. As the first enterprise certified by EU in Anhui Province, Huayi Pharma has been committed to providing sustained R&D and manufacture services for both the Chinese and European markets.

During the five-day EU inspection, Huayi Pharma once again demonstrated its outstanding quality management and production capabilities. The EU inspectors conducted a comprehensive and detailed inspection, strictly reviewed the company’s quality management system, with whole processes and all aspects covered.

The inspectors highly recognized Huayi's quality management system and site management, and also commended our team for its efficient and orderly organization and open and honest attitude during the on-site inspection. Moreover, the inspectors provided valuable recommendations and feedback on the company’s management systems and quality controls etc. A robust quality system not only reflects corporate social responsibility but also significantly strengthens clients’ trust in project cooperation and business dealings. Additionally, Huayi’s steady development fully reflects its commitment and ability to become the preferred CDMO for clients.

With the continuous innovation and rapid development of the global pharmaceutical industry, Huayi will continue advancing its internationalization. Guided by its corporate values of "create value and benefit for the world" and its spirit of "keep pragmatic and innovative all the time", Huayi is dedicated to ensuring product quality, providing clients with high-efficient, high-quality, and cost-controllable generic drug R&D and manufacture services and striving to build an open and international CDMO platform.